PTP4A3 and cancer: Because PRL3-zumab blocked PRL3+ tumors in vivo, we then investigated if PRL3-zumab could inhibit the growth of PRL3+ cancer cells in vitro: MHCC-LM3 (PRL3+; Fig. 1c) or Hep53.4-PRL3 cells (ectopic PRL3+; Fig. 1e) by adding high doses (up to 50 μg mL−1) of PRL3-zumab directly to cultured cells.